Clinical Trials Logo

Filter by:
NCT ID: NCT03704077 Withdrawn - Gastric Cancer Clinical Trials

An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

Start date: October 31, 2019
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the effectiveness of relatlimab plus nivolumab, alone or in combination with various standard-of-care treatments in participants with gastric cancer (GC) or gastroesophageal junction (GEJ) adenocarcinoma that has come back or spread to other places in the body after prior therapy.

NCT ID: NCT03698448 Withdrawn - Cystic Fibrosis Clinical Trials

A Dose-finding Study of Inhaled OligoG vs Placebo in Patients With Cystic Fibrosis

SMR3372
Start date: September 1, 2021
Phase: Phase 2/Phase 3
Study type: Interventional

Randomized, double blind, placebo controlled study. The study has two parts: Dose-finding part, followed by longer term follow-up (6 months)

NCT ID: NCT03668665 Withdrawn - Wound Heal Clinical Trials

Influencing Wound Healing Through the Application of Hyaluronic Acid With Perfluorodecalin and Physalis Angulata Extract After Split Skin Removal From the Thigh - A Study in "Split Wound Design"

Split Wound
Start date: October 2018
Phase: Phase 3
Study type: Interventional

The study will use a split wound design to investigate whether secondary wound healing can be accelerated and improved by the application of hyaluronic acid combined with perfluorodecalin and Physalis angulata extract.

NCT ID: NCT03515785 Withdrawn - Clinical trials for BCR-ABL Positive Acute Lymphoblastic Leukemia

A Study to Evaluate Effectiveness and Safety of Ponatinib in Patients With BCR-ABL Positive ALL in Standard Clinical Practice in Europe - "POSEIDON"

Start date: December 31, 2018
Phase:
Study type: Observational

The purpose of this study is to evaluate the effectiveness and safety of ponatinib (Iclusig®) in patients with BCR-ABL positive acute lymphoblastic leukemia (ALL) in standard clinical practice in Europe.

NCT ID: NCT03504033 Withdrawn - Clinical trials for Liver Function After Partial Liver Resection

Xenon-anesthesia on Patients Undergoing Major Liver-resection

XeLiv
Start date: April 11, 2018
Phase: Phase 4
Study type: Interventional

The aim of this study is to compare the postoperative outcome of patients undergoing major liver resection under xenon- compared to desflurane-anesthesia.

NCT ID: NCT03438500 Withdrawn - Clinical trials for Coronary Artery Disease

Cardiac Shock Wave Treatment in Patients With Reduced Coronary Flow Reserve

Start date: September 1, 2022
Phase: N/A
Study type: Interventional

The purpose of the study is to assess the feasibility of Cardiac Shock Wave Treatment in patients with anginal chest pain and evidence of abnormal myocardial perfusion under stress in the absence of significant stenoses of the epicardial coronary arteries.

NCT ID: NCT03437330 Withdrawn - Clinical trials for Type2 Diabetes Mellitus

Empagliflozin Effect on Glucose Toxicity

Start date: October 27, 2021
Phase: Phase 4
Study type: Interventional

Empagliflozin effect on glucose toxicity in type 2 diabetes patients - a randomized, open-label, controlled, parallel group, exploratory study

NCT ID: NCT03423355 Withdrawn - Clinical trials for Type 2 Diabetes Mellitus (T2DM)

Dapagliflozin Effect on Erythropoiesis and Physical Fitness

Start date: September 2021
Phase: Phase 4
Study type: Interventional

Dapagliflozin effect on erythropoiesis and physical fitness in patients with type 2 diabetes - a randomized, partly double-blinded, controlled, three armed, parallel group, exploratory study

NCT ID: NCT03418116 Withdrawn - Clinical trials for Retinitis Pigmentosa

Argus II Retinal Prosthesis System - Better Vision RP Study

Start date: November 1, 2018
Phase: N/A
Study type: Interventional

The study is conducted to evaluate the safety and benefit of the Argus II System in a selected patient population with advanced Retinitis Pigmentosa who have a measurable central residual visual field smaller than or equal to 5 degrees radius.

NCT ID: NCT03417037 Withdrawn - Lung Cancer Clinical Trials

An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer

Start date: May 24, 2018
Phase: Phase 3
Study type: Interventional

This is a study of experimental medication BMS-986205 given with Nivolumab with or without chemotherapy compared to chemotherapy in participants with previously untreated stage IV or recurrent non-small cell lung cancer.